Some expect the next few years will be an overall down period for pharma growth. So, Fierce’s Kevin Dunleavy invited Harietta Eleftherochorinou, Ph.D., of IQVIA to "The Top Line" to discuss why pharma needs to employ artificial intelligence and machine learning tools to stay ahead of the curve.

To learn more about the topics in this episode: 
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products
Covis finally pulls preterm birth drug Makena after 12-year accelerated approval odyssey
FDA sounds out de novo clearance for neuromodulation device to treat tinnitus
FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands
Sarissa's overhaul of Amarin's board is complete with resignation of 7 holdover members
AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff
FDA delays BioMarin's gene therapy approval decision by 3 months

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Some expect the next few years will be an overall down period for pharma growth. So, Fierce’s Kevin Dunleavy invited Harietta Eleftherochorinou, Ph.D., of IQVIA to "The Top Line" to discuss why pharma needs to employ artificial intelligence and machine learning tools to stay ahead of the curve.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/2023-forecast-inflection-point-biopharma-fueled-flood-ai-and-ml-products#:~:text=Precedence%20Research%20estimates%20that%20the,from%202021%20(%2411.1%20billion)">2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products</a></li>
<li><a href="https://www.fiercepharma.com/pharma/covis-premature-birth-drug-makena-belatedly-sidelined">Covis finally pulls preterm birth drug Makena after 12-year accelerated approval odyssey</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/fda-sounds-out-de-novo-clearance-neuromodulation-device-treat-tinnitus">FDA sounds out de novo clearance for neuromodulation device to treat tinnitus</a></li>
<li><a href="https://www.fiercepharma.com/marketing/fda-widens-lilly-verzenio-breast-cancer-removes-test-menopausal-status">FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands</a></li>
<li><a href="https://www.fiercepharma.com/pharma/sarissas-overhaul-amarins-board-complete-resignation-7-holdover-members">Sarissa's overhaul of Amarin's board is complete with resignation of 7 holdover members</a></li>
<li><a href="https://www.fiercepharma.com/pharma/abbvie-ceo-gonzalez-scores-26m-2022-pay-last-run-humira-us-exclusivity">AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff</a></li>
<li><a href="https://www.fiercepharma.com/pharma/fda-extends-review-biomarins-roctavian-three-months">FDA delays BioMarin's gene therapy approval decision by 3 months</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement